Treatment resistance analysis reveals GLUT-1-mediated glucose uptake as a major target of synthetic rocaglates in cancer cells

Julia Sieber-Frank¹,² | Hans-Jürgen Stark¹,² | Simon Kalteis¹,² |
Elena-Sophie Prigge¹,² | Richard Köhler¹,² | Carolin Andresen¹,²
Thomas Henkel³ | Georg Casari⁴ | Tobias Schubert⁴ | Wolfgang Fischl⁴ |
Min Li-Weber⁵ | Peter H. Krammer⁵ | Magnus von Knebel Doeberitz¹,² |
Jürgen Kopitz¹,² | Matthias Kloor¹,² | Aysel Ahadova¹,²

¹Department of Applied Tumor Biology, Institute of Pathology, University of Heidelberg, Heidelberg, Germany
²Collaboration Unit Applied Tumor Biology, German Cancer Research Center (DKFZ), Heidelberg, Germany
³IMAX Discovery GmbH, Konstanz, Germany
⁴Haplogen GmbH, Vienna, Austria
⁵Tumor Immunology Program, German Cancer Research Center (DKFZ), Heidelberg, Germany

Correspondence
Julia Sieber-Frank and Aysel Ahadova, Department of Applied Tumor Biology, Institute of Pathology, University of Heidelberg, Im Neuenheimer Feld 224, 69120 Heidelberg, Germany. Email: julia.sieber-frank@med.uni-heidelberg.de (J. S. F.); aysel.ahadova@med.uni-heidelberg.de (A. A.)

Funding information
Else Kröner-Fresenius-Stiftung, Grant/Award Number: 2016_A61; Hector Stiftung, Grant/Award Number: M84

Abstract
Rocaglates are natural compounds that have been extensively studied for their ability to inhibit translation initiation. Rocaglates represent promising drug candidates for tumor treatment due to their growth-inhibitory effects on neoplastic cells. In contrast to natural rocaglates, synthetic analogues of rocaglates have been less comprehensively characterized, but were also shown to have similar effects on the process of protein translation. Here, we demonstrate an enhanced growth-inhibitory effect of synthetic rocaglates when combined with glucose anti-metabolite 2-deoxy-D-glucose (2DG) in different cancer cell lines. Moreover, we unravel a new aspect in the mechanism of action of synthetic rocaglates involving reduction of glucose uptake mediated by downregulation or abrogation of glucose transporter GLUT-1 expression. Importantly, cells with genetically induced resistance to synthetic rocaglates showed substantially less pronounced treatment effect on glucose metabolism and did not demonstrate GLUT-1 downregulation, pointing at the crucial role of this mechanism for the anti-tumor activity of the synthetic rocaglates. Transcriptome profiling revealed glycolysis as one of the major pathways differentially regulated in sensitive and resistant cells. Analysis of synthetic rocaglate efficacy in a 3D tissue context with a co-culture of tumor and normal cells demonstrated a selective effect on tumor cells and substantiated the mechanistic observations obtained in cancer cell lines. Increased glucose uptake and metabolism is a universal feature across different tumor types. Therefore, targeting this feature by synthetic rocaglates could represent a promising direction for exploitation of rocaglates in novel anti-tumor therapies.
INTRODUCTION

Rocaglates, also known as flavaglines, are natural compounds sharing common characteristics of their chemical structure.\(^1\)\(^2\) Due to the well-characterized biological properties, including potent inhibition of translation and therefore strong anti-neoplastic potential,\(^3\)\(^-\)\(^10\) natural rocaglates and their derivatives raise significant interest as potential drug candidates for tumor treatment. However, the clinical translation of natural rocaglates for cancer treatment has been hampered by costly extraction processes providing only limited amounts of active substances. Recently, the successful chemical synthesis of rocaglates provided a unique opportunity to bring this promising cancer therapeutic agent group into clinical application.\(^11\) In contrast to natural rocaglates, the synthetic analogues are less well characterized, except for their extensively studied potential in inhibition of translation.\(^11\)\(^-\)\(^13\)

One of the very common cancer hallmarks is high glucose dependence of cancer cells, also known as Warburg effect.\(^14\)\(^,\)\(^15\) It is known that cancer cells metabolize glucose via aerobic glycolysis, which is energetically less efficient than oxidative phosphorylation. As a result, cancer cells consume substantially more glucose in comparison to normal cells. This principle already found its application in clinics for cancer diagnostics using Positron Emission Tomography, where radioactively labeled 2-deoxy-D-glucose (2DG) is applied to reveal cancer tissues.\(^16\)\(^,\)\(^17\) However, therapeutic agents efficiently targeting glucose metabolism are still lacking.

Although most previous studies reported on the effects of rocaglates related to the inhibition of translation,\(^11\)\(^,\)\(^13\)\(^,\)\(^18\)\(^,\)\(^19\) emerging evidence suggest involvement of metabolic alterations upon rocaglate treatment in cancer cells.\(^20\)\(^,\)\(^21\) However, the mechanisms of action resulting in metabolic changes in tumor cells remain elusive.

Here, we comprehensively characterize the anti-neoplastic effects of synthetic rocaglate compounds, with a particular focus on glucose metabolism in cancer cells. We examine the growth-inhibitory potential of synthetic rocaglate combination with glucose anti-metabolite 2DG. Moreover, using a haploid cell line with a genetically induced rocaglate-resistance, we demonstrate the crucial importance of glucose transporter inhibition for the anti-proliferative efficacy of synthetic rocaglates. Thus, we elucidate a new aspect in the broad spectrum of biological effects of synthetic rocaglates supporting their growth-inhibitory properties and underlining their high potential as tumor-targeting substances.

MATERIALS AND METHODS

2.1 | Cell lines

HCT116 (RRID:CVCL_0291; ECACC) and HT29 (RRID:CVCL_0320, Tumorbank of the DKFZ Heidelberg) cells were cultured in DMEM supplemented with 10% FBS, 100 U/ml penicillin and 100 µg/ml streptomycin (1% P/S). HGC178 (IMD-3-sensitive) and HGC176 (IMD-3-resistant) cells were generated from Hap1 cells by Haplogen GmbH (Vienna, Austria) using gene-trap (GT) mutagenesis and cultured in IMDM + 10% FBS + 1% P/S. Other cell lines were obtained from ECACC and cultured in: DMEM + 10% FBS + 1% P/S (CaSki (RRID:CVCL_1100), HeLa (RRID:CVCL_0030), SiHa (RRID:CVCL_0032)), RPMI1640 + 10% FBS + 1% P/S + 1% MEM-NEAA (UPCI-SCC-90 (RRID:CVCL_1899)). All cell lines were cultured at 37°C with 5% CO\(_2\). Cell lines were checked for mycoplasma contamination by PCR (Venor® GeM Classic kit). All experiments were performed with mycoplasma-free cells. Cells were cultured to a maximum of 30 passages after thawing. Cell lines were authenticated using Multiplex Cell Authentication by Multiplexion as described before.\(^22\) The SNP profiles matched known profiles.

2.2 | Substances

2DG stock solution was prepared in cell culture medium without supplements. Synthetic rocaglate derivatives (IMD-1: IMD-026259, IMD-3: IMD-026260) were kindly provided by IMAX Discovery GmbH (Konstanz, Germany). Stock solutions (20 mM) were prepared in DMSO, stored at −20°C and diluted in medium to obtain a 100 µM stock, from which 10x treatment stocks were prepared. If not indicated otherwise, IMD compounds were applied at the end concentration of 100 nM. Cisplatin stock solution (2.5 mM) was prepared in 0.9% NaCl and further diluted in medium.
2.3 | Cell viability

Cells were seeded onto a 96-well plate in vertical replicates (n = 3). After 24 h, cells were treated with different drug combinations for 48 h. MTS proliferation assay was performed with the CellTiter 96® AQueous One Solution according to the manufacturer’s instruction.

2.4 | Impedance measurement for real-time monitoring of cell growth and proliferation

As a label-free cell density monitoring method, impedance measurement was carried out using the xCELLigence system (E-Plate VIEW 96-well, 37°C, 5% CO₂). Cells were seeded in vertical replicates (n = 3) and space between wells was filled with PBS to reduce evaporation. After 24 h, treatment was started and continued up to two weeks with refreshing the medium (with/without treatment) each 48 h. Impedance values were recorded every 30 min for a total duration of 11 days and the data were analyzed using RTCA 2.0 software. Last measurement before treatment start was used for cell index normalization.

2.5 | Proliferation

Cells were seeded onto a 96-well plate (n = 3). After 24 h, cells were treated while simultaneously incubating them with 0.1 µCi/ml [methyl-³H]-thymidine (2.775 TBq/mmol, Hartmann Analytic GmbH, MT6035) for 48 h. Afterward, cells were washed with medium containing 1 mM non-labeled thymidine and lysed in 0.5 M NaOH (1 h, RT). Cell lysate was mixed with 10 ml UltimaGold Scintillation Cocktail and subjected to liquid scintillation counting (LSC). Each sample was counted until 2σ was 0.5, this setting was used for all experiments using LSC.

2.6 | Cytotoxicity

Cells were labeled for 12 h with 10 µCi/ml ³H-thymidine and, after extensive washing to remove non incorporated tracer, seeded onto a 96-well plate (n = 3). After 24 h, cells were treated for 12, 24, or 48 h with different drug combinations. As a background measurement, untreated cells were harvested before starting the treatment. To harvest the cells, medium was collected and cells were washed with medium containing 1 mM non-labeled thymidine to stop further incorporation of ³H-thymidine. Medium and wash were collected and mixed with 10 ml UltimaGold. Cells were lysed with 0.5 M NaOH (1 h, RT) and wells were washed. Lysate and wash were mixed with UltimaGold in a new scintillation vial. Medium and lysate were subjected to LSC (Figure S1).

2.7 | Glucose uptake

Cells were seeded onto 6-well plates (n = 3) and treated for 24 h before incubation with ³H-labelled 2DG (2-[¹³H]-Deoxy-D-glucose, 0.74 TBq/mmol, American Radiolabeled Chemicals Inc., 1558). Medium was removed and cells were washed with PBS. Fresh DMEM without supplements containing different glucose concentrations and 0.5 µCi/ml ³H-2DG was added (15 min, 37°C). Afterwards, cells were washed with PBS and trypsinized. After centrifugation (10 min, 290 g), cell pellets were washed with PBS and lysed in 0.2 M NaOH (4°C, overnight). Half of the cell lysate was mixed with 10 ml UltimaGold for LSC. Glucose uptake was normalized to protein (Bradford assay).

2.8 | Lactate production

Cells were seeded onto 24-well plates (n = 3) in DMEM containing 1 g/l glucose. After 20 h treatment, the medium was removed and cells were washed once with PBS before adding fresh DMEM (1 g/l glucose), continuing the treatment for 6 h. Medium was collected to measure dissolved lactate. Cells were washed with PBS and lysed (0.2 M NaOH, 4°C, overnight) for protein determination (Bradford assay). After medium processing (see Supplementary Methods), absorption at 339 nm was measured before (A1) and 30 min after (A2) addition of 100 µl L-LDH. Lactate concentration of the sample was calculated using the Lambert-Beer law. Each sample was measured in two technical replicates. Lactate concentration was normalized to protein.

2.9 | Pentose phosphate pathway activity

Parallel to glycolysis, glucose can also be metabolized through pentose phosphate pathway (PPP) generating pentoses including ribose-5-phosphate, a precursor molecule for nucleotide synthesis which serve as building blocks for DNA and RNA. To measure glucose flux into PPP, tritium incorporation from ³H-labeled glucose into RNA was analyzed. Cells were seeded onto 6-well plates (n = 3). Treatment was performed for 24 h while simultaneously incubating with 5 µCi D-³H(U)-Glucose (1.48 TBq/mmol, American Radiolabeled Chemicals Inc., ART1353). Cells were harvested and RNA extraction was performed.
using the RNeasy Mini Kit according to the manufacturer's instructions including on-column DNase I digestion. Afterwards, RNA was mixed with 10 ml UltimaGold for LSC. RNA concentration was determined using a NanoDrop 1000 spectrophotometer for normalization.

2.10 | Immunofluorescence staining

Cells were grown on BD Falcon™ Culture Slides for 48 h before starting drug treatment for 48 h. Cells were fixed using precooled 80% methanol (4°C, 5 min), before removing the plastic chamber. Dry slides were placed in precooled acetone (−20°C, 2 min) and dried at RT. 4 h prior to fixation, 10 µM nucleoside analogue EdU was added to label proliferating cells. Samples were blocked with 3% BSA solution in PBS (with 0.9 mM CaCl₂, 0.49 mM MgCl₂), if required EdU click reaction was performed according to the manufacturer's instructions. Primary antibodies in 3% BSA solution (4°C, overnight): Keratin 19 (Ks19.1, 1:20, Progen Biotechnik GmbH); Cleaved caspase-3 (Asp175, #9661, 1:100, Cell Signaling Technology); M30 CytoDEATH (12140349001, 1:20, Roche Diagnostics); GLUT-1 (RB-9052-P1, 1:200, Thermo Fisher Scientific), Cytokeratin 14 (NCL-L-LL002, 1:100, Leica Biosystems). Samples were washed with PBS with 0.02% Triton X-100, twice with PBS, and dipped into tap water. Secondary antibodies (Alexa488- donkey anti- rabbit IgG, 1:800, Thermo Fisher Scientific; Alexa488-goat anti- mouse IgG, 1:800, Thermo Fisher Scientific; Cy3-donkey anti- rabbit IgG, 1:1000, Dianova; Cy3-donkey anti- mouse IgG, 1:1000, Jackson ImmunoResearch) in 3% BSA solution containing 2 µg/ml DAPI were incubated for 30 min at 37°C followed by 30 min at RT. Described washing steps were performed and slides were mounted with Dako Fluorescent Mounting Medium.

2.11 | Bradford assay

Protein concentrations were obtained by Bradford assay in a 96-well plate using Bio-Rad Protein Assay Dye Reagent Concentrate and BSA solution (20 mg/ml) to obtain a standard curve. Cell lysates were diluted before the assay in either water (RIPA lysates) or 0.2 NaOH. Each sample was measured in 2–3 technical replicates to ensure measurement of one experiment/condition on one plate.

2.12 | Western blot

Cells treated for 48 h (T75 culture flasks, n = 3) were harvested and pellets were resuspended in 2 ml PBS. 600 µl of each triplicate were pooled for protein isolation, pelleted, and lysed in RIPA buffer containing 1% protease inhibitor. The remaining sample was pelleted and stored for transcriptome analysis. After brief sonication, protein lysates were incubated on ice (30 min), centrifuged (15 min, 4°C, 19,600 g) and concentration was determined (Bradford assay). Western blot analysis was performed as described previously. Twenty microgram protein were separated on 4–20% polyacrylamide gels and electro-blotted onto a PVDF membrane. Primary antibodies (4°C, overnight): GLUT-1 (1:300, Thermo Fisher Scientific), β-actin (1:20,000, MP Biomedicals), α-tubulin (1:2,000, Sigma-Aldrich). Secondary antibodies (1 h, RT): anti-rabbit IgG (HRP-linked, 1:2,000, Cell Signaling Technology), anti-mouse IgG (HRP-linked, 1:5,000, Cell Signaling Technology). Membranes were stripped using Restore™ Western Blot Stripping Buffer before repeating the procedure to stain actin/tubulin on the same blot.

2.13 | Statistical analysis

Statistics were performed using Prism software and data are shown as mean ± error, if not stated otherwise. Dataset were analyzed for significance using ANOVA followed by a Tukey’s multiple comparison (one-way) or Bonferroni post-test (two-way). p-values smaller 0.05 were considered significant. *p ≤ 0.05; **p ≤ 0.01; *** p ≤ 0.001; ns, non-significant.

2.14 | Transcriptome analysis

RNA was isolated from the cell pellets. Expression analysis was performed on an Illumina Human HT-12 v4 chip at the Microarray Unit of the Genomics and Proteomics Core Facility, German Cancer Research Centre (DKFZ). Data analysis of the beadarray expression profiling was carried out following the workflow in the “beadarray” package documentation vignette using R 3.6.1 and Bioconductor 3.9. Detailed data analysis is described in Supplementary Methods. The obtained list of significantly differentially gene (DEG) was used for Ingenuity Pathway Analysis (Qiagen).

2.15 | Gene-trap mutagenesis of haploid cells

Generation of IMD-3-resistant cells was performed by Haplogen GmbH (Vienna, Austria) using gene-trap (GT) mutagenesis as described previously with subsequent resistance screen for IMD-3. Detailed description is provided in Supplementary Methods.
2.16 Organotypic culture model (OTC)

The establishment and cultivation conditions of the organotypic culture model (OTC) mimicking HPV-induced precancerous lesions are detailed in a methodological paper on this recently developed model that is currently in preparation (Köhler*, Stark* et al.27). Technical details on the preparation of the supportive fibroblast-containing matrix (dermal equivalents) have been described elsewhere.28 In these OTCs, SiHa cells and normal keratinocytes were co-cultivated on dermal equivalents to form tumor cell clusters. After two weeks period of culturing, OTCs received three treatments with 0.1 or 0.5 µM IMD-3, 1 mM 2DG or the combination of IMD-3 and 2DG with 48 h intervals and were fixed 7 days after the first treatment and embedded in paraffin for sectioning. Cultures were incubated with 10 µM EdU 4 h prior to fixation.

3 RESULTS

3.1 Synthetic rocaglates reduce cell viability by inhibiting cell proliferation and inducing apoptosis

In order to unravel anti-cancer properties of synthetic rocaglates, we focused on two lead compounds from the synthetic rocaglate family (IMD-026259, IMD-026260; hereafter referred to as IMD-1 and IMD-3, respectively, Figure 1A). We first assessed the anti-tumor characteristics of these two synthetic rocaglate compounds in 22 cancer cell lines derived from different tumor tissues including colorectal, cervical, prostate, breast cancer and others (Figure 1A,B, S2A). Both substances were applied alone and in combination with 2DG (1 mM), a potent inhibitor of glucose metabolism.29-31 The most potent reduction of cell viability upon a single compound treatment was observed with IMD-3, with an average IC_{50} of 73 nM in 13 cell lines, which could be further reduced to an average of 51 nM in 17 cell lines when combined with 2DG (Figure S2B). IMD-1 and 2DG alone did not strongly reduce cell viability in most of the tested cell lines. However, the combination of IMD-1 with 2DG reduced IC_{50} of the former (Figure S2B) and exhibited an enhanced growth inhibitory effect in several cell lines (e.g., HCT116, HeLa, SiHa). To further characterize the effects of synthetic rocaglates, we focused on two colon carcinoma cell lines: a more treatment-sensitive microsatellite-unstable HCT116 (IC_{50} of IMD-3: 50 nM) and a less sensitive microsatellite-stable HT29 (IC_{50} not reached) (Figure 1C) and validated our major findings in HPV-induced cervical cancer cells lines (SiHa, CaSki, HeLa, HNSCC UPCI-SCC-90).

To characterize the influence of synthetic rocaglates on cell proliferation, cell density, and adhesion in realtime, cells were monitored over time by impedance measurement (Figure 2). In comparison to steeply increasing growth curves of cells treated with vehicle or 2DG, the descending growth curves of IMD-3-treated cells reflecting reduction of the impedance values indicated proliferation inhibition. When IMD-3 treatment was discontinued, the effect was preserved for 48–72 h after treatment interruption and could be restored upon treatment re-application (Figure 2A,B). In contrast, IMD-1 even upon continuous treatment merely caused a delay in cell outgrowth, but did not substantially influence the cell density after 120 h (Figure 2), whereas continuous treatment with IMD-3 prevented the HCT116 and HT29 cells from re-growing (Figure 2C). Next, we asked what main mechanisms are responsible for cancer cell growth inhibition upon treatment with synthetic rocaglates. The ^3H-thymidine incorporation assay showed that the large proportion of the induced effect was caused by proliferation inhibition, whereas only a minor effect could be attributed to direct cytotoxicity in the treated cells (Figure 2D,E, S3). Proliferation inhibition was confirmed in HPV-transformed cervical cancer cells (Figure S4). In addition, cells treated with IMD-3 showed phenotypic hallmarks of apoptosis, such as expression of cleaved caspase-3 and caspase-cleaved cytokeratin 18 (Figure 2F).

3.2 Synthetic rocaglates inhibit glucose metabolism through reduction of GLUT-1 expression

Previously, natural rocaglates were suggested to influence glucose flux into cancer cells.20 As we observed an enhanced growth-inhibitory effect of IMD-3 when combined with 2DG, we asked, whether glucose metabolism is influenced also by synthetic rocaglates. We first measured glucose uptake upon IMD treatment using radioactive ^3H-2DG as tracer and found that treatment with synthetic rocaglates reduced glucose uptake velocity (Figure 3A, S4C). In line with a more potent effect of IMD-3 compared to IMD-1 on cell viability, glucose uptake was more strongly inhibited in IMD-3-treated cells. Consequently to reduction of glucose uptake, the glycolytic activity of cells was more substantially reduced upon treatment with IMD-3. Importantly, the combination of IMD-3 and 2DG almost completely abolished the glycolytic activity in treated cells (Figure 3B, S4D).

To examine the possible mechanisms, through which glucose uptake is deregulated in cancer cells upon treatment, we investigated the expression of the most abundant glucose transporter GLUT-1, known to be overexpressed
in the majority of tumors. Strikingly, cellular GLUT-1 protein expression was significantly downregulated or completely eliminated upon IMD-3 treatment, whereas 2DG treatment did not alter the expression of GLUT-1 (Figure 3C), which fits to the hexokinase inhibition-based anti-glycolytic function of 2DG. This finding was validated by the immunofluorescent staining of treated cells revealing loss of membranous GLUT-1 expression upon IMD-3 treatment (Figure 3D, S4B).

As glucose metabolism links together catabolic and anabolic pathways in cells, it is important to analyze possible treatment-related re-direction of glucose from energy-producing into nucleic acid building blocks-generating pathways, such as pentose phosphate pathway (PPP). However, the incorporation of glucose chemical derivatives into nucleic acids was not increased but decreased upon treatment with IMD-3, indicating no shift of glucose metabolism toward the anabolic pathways upon IMD-3-related glycolysis inhibition, and reflecting rather the generally decreased glucose flux (Figure 3E). Lack of required precursor molecules such as ribose-5-phosphate for nucleotide and nucleic acid synthesis also explains the observed proliferation inhibition upon synthetic rocaglate treatment.

In general, both cell lines demonstrated inhibition of glucose metabolism; consistent with the higher treatment sensitivity of HCT116 cells compared to HT29, the effects of IMD-3 on glucose metabolism were more pronounced in HCT116 cells.

3.3 | Gene-trapped treatment-resistant cells do not exhibit deregulation of glucose metabolism

To elucidate possible genetic mechanisms behind the efficacy of synthetic rocaglates, especially IMD-3, a
FIGURE 2  Inhibition of cell proliferation and apoptosis induction in HCT116 and HT29 cells upon treatment. (A) Real-time proliferation monitoring of cells treated for 48 h before changing back to drug-free medium. The peaks of the cell index result from changing the medium, and fluctuations of the cell index result from the overconfluence of the cells treated with vehicle or less efficient substances. (B) Real-time proliferation monitoring of cells treated for 48 h before interrupting the treatment for 96 h followed by treatment re-application. (C) Real-time proliferation monitoring of cells continuously treated for 11 days. Mean values of cell proliferation are shown for cell index values to increase readability of the data. (D) Proliferation inhibition during 48 h of treatment measured by ³H-thymidine incorporation. (E) Cytotoxic cell death induced by treatment in HCT116 cells based on the release of ³H-thymidine. Spontaneous cell death (release observed in control cells) was subtracted to obtain cytotoxic cell death of each substance (Figure S3). (F) Immunofluorescence staining for apoptosis using cleaved caspase-3 (red) and caspase-cleaved cytokeratin 18 (green). Nuclei were DAPI-stained. Magnification: 400-fold. 2DG: 1mM, IMD-1: 100 nM, IMD-3: 100 nM, Cisplatin: 75 µM. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ns, non-significant.
resistant haploid cell line was generated using gene-trap (GT) mutagenesis for high-throughput genetic resistance screening (Figure 4A). For gene-trap mutagenesis, upon random insertion of a cassette consisting of splice acceptor, reporter gene, a termination sequence and short unique DNA sequence (barcode) into intronic gene regions of treated cells, a fusion transcript is generated leading to an impaired expression of the trapped gene. Next, if any cells became resistant to treatment upon mutagenesis, massive parallel sequencing (NGS)

FIGURE 3  Influence of synthetic rocaglates on glucose metabolism. (A) Glucose uptake velocity upon synthetic rocaglate treatment (24 h) dependent on the glucose concentration in the medium using radioactive ^3^H-2DG. (B) Amount of secreted lactate by IMD-treated cells after 24 h of treatment. Inhibition of glycolysis shown by reduced amount of secreted lactate upon 2DG treatment can be observed in both cell lines, whereas of both rocaglates only IMD-3 is able to inhibit glycolysis. (C) Western blot analysis of GLUT-1 (45–55 kDa) showing decreased (HT29) to abolished (HCT116) expression upon IMD-3 treatment. (D) Immunofluorescent staining of glucose transporter GLUT-1 (green) and the proliferation marker EdU (red) showing reduced GLUT-1 expression and proliferation inhibition by IMD-3 treatment of cancer cells. Nuclei were DAPI stained. Magnification: 400-fold. (E) PPP activity measured by radioactivity of ^3^H added to the cells in form of ^3^H-labeled glucose and later incorporated into RNA. ^p^ ≤ 0.05; ** ^p^ ≤ 0.01; *** ^p^ ≤ 0.001; ns, non-significant. 2DG: 1 mM, IMD-1: 100 nM, IMD-3: 100 nM
was applied to identify the trapped gene possibly responsible for resistance formation. Using this approach, we were able to obtain cells that became resistant to IMD-3 treatment after GT mutagenesis, which were further cultured and established as a resistant cell line (HGC176) from an original wild type (WT) cell line HGC178.

To check, whether the induced resistance against IMD-3 treatment is merely transient or remains stable over time, both WT HGC178 and resistant HGC176 cells were cultured over a period of more than 5 weeks and treatment sensitivity was compared between cells from low and high passages. Importantly, the HGC176 cell line showed stable resistance towards IMD-3 as demonstrated by consistent cell viability in growing cell passages (Figure 4B). In sharp contrast to WT HGC178 cells, proliferation in resistant HGC176 cells was not influenced by IMD-3 treatment (Figure 4C). Treatment with 2DG alone also had no pronounced effect on cell proliferation in both cell lines, whereas combination of 2DG with IMD-3 showed a slightly enhanced anti-proliferative effect in both cell lines. Moreover, real-time proliferation monitoring by impedance assay confirmed the observed stable resistance of HGC176 cells against IMD-3 in long-term (11 days) experiments with different treatment schemes (Figure 4D). Here, HGC176 cells retained resistance also after interruption and re-application of treatment with IMD-3, whereas HGC178 cells remained sensitive (Figure 4D, lower panel). However, the sequencing analysis did not identify a gene responsible for resistance, pointing toward a genetics-independent resistance mechanism sustaining IMD-3 resistance during continuous passages in the absence of IMD-3 (Figure S5A).

We then analyzed whether IMD-3-resistant cells show glucose metabolism alterations described above in the HCT116 and HT29 cell lines. The comparison between WT HGC178 and resistant HGC176 cell lines revealed substantially less pronounced reduction of glucose uptake upon treatment in HGC176 (Figure 4E, S5B). Also, in contrast to dramatic reduction of glucose flux into PPP pathway in the WT cell line, the effect of IMD-3 treatment was significantly less pronounced in the resistant HGC176 cell line \( (p \leq 0.001) \) compared to the WT cells (Figure 4F). Noteworthy, the effect of 2DG on PPP in resistant cells was weaker compared to sensitive cells \( (p \leq 0.001) \). Importantly, protein levels of GLUT-1 remain unaffected in HGC176 cells upon IMD-3 treatment (Figure 4G). Taken together, these observations point out the important role of glucose metabolism inhibition and GLUT-1 downregulation in the anti-tumor efficacy of IMD-3.

### 3.4 Treatment with synthetic rocaglates leads to alteration of metabolic pathway genes

As the gene sequencing did not reveal a certain genetic alteration possibly responsible for resistance development, we performed RNA transcriptome analysis to detect altered pathways.

Pathway analysis revealed that IMD-3 treatment influenced similar pathways in all treatment-sensitive cell lines (HCT116, HT29, HGC178, CaSki, HeLa, SiHa, UPCI-SCC-90), whereas those pathways were not deregulated in IMD-3-resistant HGC176 cells (Figure 5A, B). Similar to natural rocaglates, which were found to promote ER stress leading to apoptosis, IMD-3 strongly induced “unfolded protein response” pathway indicating ER stress (Figure 5B), confirming our observation of IMD-3-induced apoptosis. Additionally, NRF2-mediated oxidative stress response was upregulated upon IMD-3 treatment, whereas glutathione (GSH) pathways were downregulated (Figure 5A, B), indicating a depletion of GSH and accumulation of ROS in sensitive cells, which has been previously found to induce apoptosis. GSH depletion could be mediated by inhibition of the PPP upon synthetic rocaglate treatment decreasing cellular NADPH levels, thus hampering the activity of glutathione reductase enzyme, which catalyzes the reduction of glutathione disulfite (GSSG) to GSH.

Heat shock Factor 1 (HSF1) is a master regulator of transcriptional programs linking the translational flux to the metabolic state of the cells and enabling the adaptation to the high anabolic demands of cancer cells. Interestingly, IMD-3 treatment resulted in decreased levels of the heat shock protein family member HSPA8 (4-fold) in HCT116 cells, indicating translation inhibition, whereas HSPA8 was increased in resistant HGC176 cells upon treatment (2.8-fold), representing the most upregulated gene. At the same time, HT29 showed a 10-fold increase in expression levels of TXNIP, a negative regulator of glucose flux, upon treatment, which was also increased in all four HPV-transformed cell lines. Furthermore, observed downregulation of GLUT-1 on protein level was also detected in HPV-transformed CaSki cells on the transcriptome level (2.3-fold, Table S1). Transcriptome analysis further showed inhibition of oxidative phosphorylation by downregulation of electron transport chain genes through IMD-3 treatment, especially downregulation of the complex I assembly factor NDUFAF3, or complex II subunit SDHC (Table S1). Comparison of all significantly differentially expressed genes (DEGs) upon IMD-3 treatment between cell lines revealed that 137 genes were regulated in the same direction in all tested treatment-sensitive cell
In the present study, we demonstrate inhibition of glucose metabolism as a key biological mechanism of action of synthetic rocaglates, particularly of IMD-3 (IMD-026260). We found that IMD-3 restricts glucose uptake through inhibition of glucose transporter GLUT-1 expression, leading to hampered glycolysis, apoptosis induction and inhibition of cell proliferation.

Deregulation of cellular metabolism displays a common hallmark for different tumor types fueling tumor
To match their increased glucose requirements, cancer cells increase their glucose uptake through upregulation of glucose transporters, especially GLUT-1 with a high affinity for glucose. This mechanism had direct clinical implications: for instance, tamoxifen treatment in breast cancer patients was shown to downregulate glycolysis and GLUT-1 expression, whereas high expression of GLUT-1 was linked to poor prognosis in patients with oral squamous cell carcinomas. Thus, GLUT-1 may represent a promising protein for targeting high glucose consumption of cancer cells.
By employing GT mutagenesis we generated a cell line stably resistant against treatment with IMD-3, representing a valuable model for studying mechanisms of action of synthetic rocaglates. Using this newly generated GT cell line, we were able to demonstrate downregulation of GLUT-1 as a crucial biological effect of IMD-3 treatment, as in sharp contrast to the tested sensitive cell lines, the IMD-3-resistant cell line did not show GLUT-1 downregulation upon treatment. In fact, RNA transcriptome data supported these results revealing an a priori downregulation of glycolysis in IMD-3-resistant cells, further substantiated by decreased sensitivity of IMD-3-resistant cells towards 2DG. Thus, downregulated glycolysis prevented further inhibition of glucose metabolism by treatment, suggesting a predictive role of the enhanced baseline glucose turnover and GLUT-1 expression for the IMD-3 treatment success. Importantly, treatment-related reduction in glycolytic activity in the sensitive cell lines did not result in the redirection of the available glucose into pentose phosphate pathway, further suggesting the general restriction of glucose availability for diverse downstream pathways upon treatment.

Together with glycolysis, translation initiation, previously shown to be strongly hampered by natural and synthetic rocaglates, was among the top five pathways downregulated in the resistant cell line compared to the sensitive WT cell line. These observations are in line with previous reports demonstrating a connection between translation inhibition, a well-studied feature of natural and synthetic rocaglates, and glucose metabolism. Santagata et al. first reported inhibition of glucose flux in cancer cells upon translation inhibition induced by treatment with rocaglates, which was mediated by inactivation of HSF1 and subsequent upregulation of TXNIP, one of the main negative regulators of glucose uptake. Our transcriptome data showing decreased expression of HSPA8 and increased expression of TXNIP upon treatment with synthetic rocaglates further support the previously suggested fundamental link between anabolic and catabolic processes in cancer cells. Besides GLUT-1 downregulation demonstrated on protein and mRNA levels, other glucose transporters such as GLUT-5 (in CaSki, HeLa) and GLUT-6 (in HCT116, HeLa), which are less expressed in these tumors and therefore presumably are less relevant for glucose uptake in these tissues also showed downregulation upon IMD-3 treatment on transcriptome level. GLUT-6 has also been previously shown to be downregulated upon treatment of pancreatic tumor tissues with another synthetic rocaglate compound. These observations underline a general character of synthetic rocaglate-induced glucose transporter inhibition, which is likely to be most pronounced in the abundantly represented transporter molecules of the respective tissue. Taken together, these findings show that glycolysis and translation initiation are the major target pathways of synthetic rocaglates, although direct interaction of synthetic rocaglate with 2DG and synthetic rocaglates. (A) Decreased growth and viability of tumor cell clusters in treated OTCs visualized in HE staining. (B) Fluorescence staining of OTCs showing reduced glucose transporter GLUT-1 (green) levels and decreased proliferation (EdU, red). (C) Fluorescence staining for cleaved caspase-3 (green) indicates apoptosis induction. Keratinocytes are stained for cytokeratin 14 (red). Nuclei are stained with DAPI (blue).
rocaglates with a specific target molecule remains to be discovered.

In addition to inhibition of translation initiation and glycolysis, we found downregulation of GSH-related pathways and upregulation of NRF2-mediated oxidative stress response pathway upon IMD-3 treatment, leading to apoptosis. Similar findings were reported in a recent study by Chan et al. focusing on another synthetic rocaglate CR-31,21 suggesting common traits in the mechanisms of action of synthetic rocaglates with different chemical structure. Cancer evolution is based on the survival of the fittest clone, thus multiple adaptation tools are exploited by cancer cells in order to survive under certain conditions. Thus, it is not surprising that under IMD-3 treatment, which deprives cells of glucose, mRNAs levels of genes involved in glutamine metabolism, which serves as an alternative fuel, are increased, presumably, shifting cellular metabolism towards glutamine consumption. In line with this assumption, combination of synthetic rocaglates with glutaminase inhibitor previously showed promising results,21 although the influence of IMD-3 on glutamine metabolism and potential combination with glutaminase inhibitors needs to be further investigated in future studies. Furthermore, pathway analysis revealed alterations of other metabolic pathways upon IMD-3 treatment, such as fatty acid metabolism, which shall be further investigated in the future to elucidate the general influence of synthetic rocaglates on cellular metabolism.

Our study has strengths and limitations. Major strength is demonstration of the importance of glucose metabolism for the successful treatment with IMD-3 using a therapy-resistant in vitro cancer model, leading to emergence of possible therapy-relevant predictive markers, such as GLUT-1. Moreover, we for the first time demonstrate that the effect of synthetic rocaglates can be enhanced by combination with 2DG, a well-studied substance tested in several clinical trials, which so far could not be admitted for clinical application due to limited anti-tumor effect at non-toxic doses.29,45 We also validated our mechanistic observations in an independent set of cancer cells lines from a different cancer entity, further pointing at the generalizable character of the reported findings for several molecularly and clinically distinct tumors. Furthermore, we could demonstrate the efficacy of synthetic rocaglates in a 3D co-culture model. This model revealed a selective effect of IMD-3 on the tumor cells and confirmed the mechanistic characteristics of the treatment observed in 2D culture, such as downregulation of GLUT-1 expression and reduction of cell growth and viability via inhibition of proliferation and induction of apoptosis. The different responsiveness of tumor cells and normal cells indicates a potential therapeutic window for synthetic rocaglates. In addition to pointing at the selective character of the treatment, decreased sensitivity of keratinocytes might result from the decreased metabolic rate in skin46 rendering them less sensitive towards the influence of synthetic rocaglates on cellular metabolism. Therefore, 3D tumor models including other normal cells should be used to further validate the selective anti-tumor effect of synthetic rocaglates. Such studies also need to address the mechanisms responsible for differences in effective drug concentrations between 2D and 3D tumor models, which may be related to impeded diffusion and decreasing drug concentration gradient towards tumor cells occurring in 3D, but not 2D models. Moreover, in vivo studies evaluating the treatment parameters not addressable in 2D and 3D tumor models are warranted for further evaluating the potential of synthetic rocaglates as anti-tumor compounds. Analysis of only two synthetic rocaglates compounds is one limitation of our study. In addition, the in vivo efficacy of the synthetic rocaglate treatment should be analyzed in future studies, also investigating the potential effect of combination with 2DG, which could possibly pave the way towards clinical translation of both compounds.

In summary, our study shows that compounds targeting glucose uptake and inhibiting glucose metabolism in cancer cells represent a promising direction for development of cancer-therapeutic approaches and suggests synthetic rocaglates, particularly IMD-3, as candidate compounds with strong anti-cancer potential.

ACKNOWLEDGMENTS
We thank the Microarray Unit of the Genomics and Proteomics Core Facility, German Cancer Research Center (DKFZ), for providing excellent Expression Profiling services. The excellent technical assistance of Sigrun Himmelsbach, Laura Brandschwei and Nina Nelius is gratefully acknowledged. This study was performed with grant support of Else-Kröner-Fresenius Stiftung (2016_A61) and Hector Stiftung (M84).

CONFLICTS OF INTEREST
E.S.P. has received lecture fees by MSD SHARP & DOHME GmbH and Institut für Frauengesundheit (IFG) GmbH. E.S.P. is involved in a research project funded by MSD SHARP & DOHME GmbH outside the submitted work.

ORCID
Julia Sieber-Frank © https://orcid.org/0000-0003-3189-1443
Carolin Andresen © https://orcid.org/0000-0002-8960-7719
Aysel Ahadova © https://orcid.org/0000-0001-9890-0450
REFERENCES

1. Kim S, Salim AA, Swanson SM, Kinghorn AD. Potential of cyclopenta[b]benzofurans from Aglaia species in cancer chemotherapy. *Anticancer Agents Med Chem.* 2006;6:319-345.

2. Pan L, Woodard JL, Lucas DM, Fuchs JR, Kinghorn AD. Rocaglamide, silvestrol and structurally related bioactive compounds from Aglaia species. *Natural Product Rep.* 2014;31:924-939.

3. Li-Weber M. Molecular mechanisms and anti-cancer aspects of the medicinal phytochemicals rocaglamides (=flavaglines). *Int J Cancer.* 2015;137:1791-1799.

4. Polier G, Neumann J, Thuaud F, et al. The natural anticancer compounds rocaglamides inhibit the Raf-MEK-ERK pathway by targeting prohibitin 1 and 2. *Chem Biol.* 2012;19:1093-1104.

5. Bordeleau ME, Robert F, Gerard B, et al. Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. *J Clin Investig.* 2008;118:2651-2660.

6. Iwasaki S, Floor SN, Ingolia NT. Rocaglamides convert DEAD-box protein eIF4A into a sequence-selective translational repressor. *Nature.* 2016;534:558-561.

7. Becker MS, Muller PM, Bajorat J, et al. The anticancer phytochemical rocaglamide inhibits Rho GTPase activity and cancer cell migration. *Oncotarget.* 2016;7:51908-51921.

8. Wu Y, Giaisi M, Kohler R, Chen WM, Krammer PH, Li-Weber M. Rocaglamide breaks TRAIL-resistance in human multiple myeloma and acute T-cell leukemia in vivo in a mouse xenograft model. *Cancer Lett.* 2017;389:70-77.

9. Neumann J, Boerries M, Kohler R, et al. The natural anticancer compound rocaglamide selectively inhibits the G1-S-phase transition in cancer cells through the ATM/ATR-mediated Chk1/2 cell cycle checkpoints. *Int J Cancer.* 2014;134:1991-2002.

10. Chang L-S, Oblinger JL, Burns SS, et al. Targeting protein translation by rocaglamide and didesmethylrocaglamide to treat MPNST and other sarcomas. *Mol Cancer Ther.* 2020;19:731-741.

11. Chu J, Zhang W, Cencic R, et al. Rocaglamides induce gain-of-function alterations to eIF4A and eIF4F. *Cell Rep.* 2020;30(2481–8):e5.

12. Chu J, Zhang W, Cencic R, et al. Amidino-rocamalates: a potent class of eIF4A inhibitors. *Cell Chem Biol.* 2019;26(5):1586–93:e3.

13. Iyer KR, Whitesell L, Porco JA Jr, et al. Translation inhibition by rocaglamides activates a species-specific cell death program in the emerging fungal pathogen candida auris. *MBio* 2020;11:e03329-19.

14. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. *J General Physiol.* 1927;8:519-530.

15. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell.* 2011;144:646-674.

16. Gambhir SS. Molecular imaging of cancer with positron emission tomography. *Nat Rev Cancer.* 2002;2:683-693.

17. Czernin J, Phelps ME. Positron emission tomography scanning: current and future applications. *Annu Rev Med.* 2002;53:89-112.

18. Zhang X, Bi C, Lu T, et al. Targeting translation initiation by synthetic rocaglamates for treating MYC-driven lymphomas. *Leukemia.* 2020;34:138-150.

19. Bleumink M, Kohler R, Giaisi M, Proksch P, Krammer PH, Li-Weber M. Rocaglamide breaks TRAIL resistance in HTLV-1-associated adult T-cell leukemia/lymphoma by translational suppression of c-FLIP expression. *Cell Death Differ.* 2011;18:362-370.

20. Santagata S, Mendillo ML, Tang Y-C, et al. Tight coordination of protein translation and HSF1 activation supports the anabolic malignant state. *Science.* 2013;341:1238303.

21. Chan K, Robert F, Oertlin C, et al. eIF4A supports an oncogenic translation program in pancreatic ductal adenocarcinoma. *Nat Commun.* 2019;10:5151.

22. Castro F, Dirks WG, Fahnhrich S, Hotzen-Wagenblatt A, Pawlita M, Schmitt M. High-throughput SNP-based authentication of human cell lines. *Int J Cancer.* 2013;132:308-314.

23. Lee J, Ballikaya S, Schonig K, et al. Transforming growth factor beta receptor 2 (TGFBRII) changes sialylation in the microsomal unstable (MSI) Colorectal cancer cell line HCT116. *PLoS One.* 2013;8:e50704.

24. Dunning MJ, Smith ML, Ritchie ME, Tavare S. beadarray: R classes and methods for Illumina bead-based data. *Bioinformatics.* 2007;23:2183-2184.

25. Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res.* 2015;43:e47.

26. Bürkstümmer T, Banning C, Hainzl P, et al. A reversible gene trap collection empowers haploid genetics in human cells. *Nat Methods.* 2013;10:965-971.

27. Köhler R, Stark HJ, von Knebel DM, Prigge ES. A novel organotypical culture as a novel 3D Model for Head and Neck Squamous Cell Carcinoma. *Cancers.* 2020;12.

28. Engelmann L, Thierauf J, Koeichert laureano N, et al. Organotypic Co-Cultures as a Novel 3D Model for Head and Neck Squamous Cell Carcinoma. *Cancers.* 2020;12.

29. Stein M, Lin H, Iyer KR, et al. Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies. *Prostate.* 2010;70:1388-1394.

30. Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. *Oncogene.* 2006;25:4633-4646.

31. Mahler JC, Krishan A, Lampidis TJ. Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-D-glucose in tumor cells treated under hypoxic vs aerobic conditions. *Cancer Chemother Pharmacol.* 2004;53:116-122.

32. Chan DA, Sutphin PD, Nguyen P, et al. Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. *Sci Transl Med.* 2011;3:94ra70.

33. Kunkel M, Reichert TE, Benz P, et al. Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. *Cancer.* 2003;97:1015-1024.

34. Sakasita M, Aoyama N, Minami R, et al. Glut1 expression in T1 and T2 stage colorectal carcinomas: its relationship to clinico-pathological features. *Eur J Cancer.* 2001;37:204-209.

35. Li X, Li M, Ruan H, et al. Co-targeting translation and proteasome rapidly kills colon cancer cells with mutant RAS/RAF via ER stress. *Oncotarget.* 2017;8:9280-9292.

36. Fribley A, Zhang K, Kaufman RJ. Regulation of apoptosis by the unfolded protein response. *Methods Mol Biol.* 2009;559:191-204.

37. Franco R, Cidlowski JA. Apoptosis and glutathione: beyond an antioxidant. *Cell Death Differ.* 2009;16:1303-1314.

38. Chi L, Ke Y, Luo C, Gozal D, Liu R. Depletion of reduced glutathione enhances motor neuron degeneration in vitro and in vivo. *Neuroscience.* 2007;144:991-1003.
39. Parikh H, Carlsson E, Chutkow WA, et al. TXNIP regulates peripheral glucose metabolism in humans. *PLoS Medicine*. 2007;4:e158.

40. Pakos-Zebrucka K, Koryga I, Mnich K, Ljubic M, Samali A, Gorman AM. The integrated stress response. *EMBO Rep.* 2016;17:1374-1395.

41. Teske BF, Fusakio ME, Zhou D, et al. CHOP induces activating transcription factor 5 (ATF5) to trigger apoptosis in response to perturbations in protein homeostasis. *Mol Biol Cell.* 2013;24:2477-2490.

42. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. *Cell Metab.* 2008;7:11-20.

43. Barron CC, Bilan PJ, Tsakiridis T, Tsiani E. Facilitative glucose transporters: Implications for cancer detection, prognosis and treatment. *Metab, Clin Exp.* 2016;65:124-139.

44. Rivenzon-Segal D, Boldin-Adamsky S, Seger D, Seger R, Degani H. Glycolysis and glucose transporter 1 as markers of response to hormonal therapy in breast cancer. *Int J Cancer.* 2003;107:177-182.

45. Raez LE, Papadopoulos K, Ricart AD, et al. A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. *Cancer Chemother Pharmacol.* 2013;71:523-530.

46. Gazel A, Ramphal P, Rosdy M, et al. Transcriptional profiling of epidermal keratinocytes: comparison of genes expressed in skin, cultured keratinocytes, and reconstituted epidermis, using large DNA microarrays. *J Invest Dermatol.* 2003;121:1459-1468.

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.

**How to cite this article:** Sieber-Frank J, Stark H-J, Kalteis S, et al. Treatment resistance analysis reveals GLUT-1-mediated glucose uptake as a major target of synthetic roca glates in cancer cells. *Cancer Med.* 2021;10:6807–6822. [https://doi.org/10.1002/cam4.4212](https://doi.org/10.1002/cam4.4212)